若生智能
Drug Database
FL

fluvoxamine (Favoxil CR / Favoxile CR / fluvoxamine CR)

✓ Approved

Astellas Pharma · SLC6A4 · 小分子

什么是 fluvoxamine？

fluvoxamine 是一种小分子，由Astellas Pharma研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

商品名Favoxil CR, Favoxile CR, fluvoxamine CR
公司Astellas Pharma
药物类别小分子
分子靶点SLC6A4
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, Astellas Pharma

作用机制

分子靶点

fluvoxamine 作用于 1 个分子靶点：

SLC6A4solute carrier family 6 member 4 (5HTT, 5-HTT)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

fluvoxamine 针对 2 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Psychiatric disordersObsessive-compulsive disorder✓ Approved
Psychiatric disordersSocial anxiety disorder✓ Approved

相关研究文献

PubMedRSC advances2026-08-05

Adsorption-synergized reduction of Cr(vi) using Gypsum@PANI composite: unraveling mechanism and advanced statistical physics prediction.

El Omari Samira S, Ait El Bacha Kamal K, Imgharn Abdelaziz A, Tzuc Oscar May OM et al.

Cr(vi) is categorized as a top-priority hazardous contaminant. The subsequent adsorption/reduction of Cr(vi) into Cr(iii) has emerged as a powerful process for detoxifying Cr(vi)-laden waters. Herein, a newly designed Gypsum@Polyaniline (Gypsum@PANI) composite was applied for the detoxification of Cr(vi) ions in aqueous solutions. The as-developed Gypsum@PANI composite exhibited a mesoporous texture abundantly decorated with amine/imine groups. Based on the response surface modeling, the Cr(vi) adsorption effectiveness reached 93.86% under optimized conditions (pH 2, adsorbent dosage of 0.35 g L-1, contact time of 4 h, Cr(vi) concentration of 20 mg L-1 at 25 °C). Freundlich and pseudo-second order models satisfactorily represented the Cr(vi) adsorption. The maximum uptake capacity was found to be 310.36 mg g-1. Advanced statistical physics assessment highlighted that Cr(vi) adsorption proceeded via multi-anchorage and multi-molecular pathways. Likewise, the thermodynamic functions proved the spontaneity of the adsorption process, accompanied by energy release and increased disorder. XPS analysis evidenced that the adsorbed Cr(vi) ions were reduced to the less toxic Cr(iii) form. The Gypsum@PANI demonstrated encouraging reusability with a Cr(vi) removal yield of 91% after five successive cycles. Overall, the experimental and theoretical findings asserted that the Gypsum@PANI composite has great potential for the detoxification of Cr(vi) ions in wastewater.

PMID 42553434
阅读全文 →
PubMedRSC advances2026-08-05

Cr(vi) removal performance of activated carbon (CB-AC) and nZVI-modified activated carbon (nZVI@CB-AC) derived from waste cigarette butts in aqueous solutions.

Duru Türkay T, Duman Gözde G, Coşkun Yasemin İşlek Yİ, Aksuner Nur N

This study presents and compares two highly efficient adsorbents derived from waste cigarette butts for the removal of Cr(vi) from aqueous solutions using activated carbon (CB-AC) and nZVI-modified activated carbon (nZVI@CB-AC). Both adsorbents achieved 96-99% Cr(vi) removal at a low amount of 0.03 g under optimal conditions at pH 3. The CB-AC and nZVI@CB-AC adsorbents exhibited adsorption capacities of 101.01 mg g-1 and 105.26 mg g-1, respectively. Various characterization analyses revealed the structural properties of the adsorbents and showed a high surface area. The adsorption data of the nZVI@CB-AC fitted best with the Freundlich model, as indicated by a high correlation coefficient (R 2 = 0.997). Thermodynamic analyses indicated a spontaneous and endothermic process accompanied by increased randomness at the solid-liquid interface. Selectivity studies showed that CB-AC exhibited a high Cr(vi) removal efficiency even in the presence of competing ions. XPS analysis revealed that the predominant removal mechanism was a redox interaction between Cr(vi) ions and nZVI@CB-AC, which contributed to the adsorbent's higher capacity, faster kinetics, and improved efficiency. Overall, this research emphasized both CB-AC and nZVI@CB-AC as promising and effective adsorbents for Cr(vi) removal from aqueous environments.

PMID 42553492
阅读全文 →
PubMedBiological trace element research2026-08-05

Monitoring and Human Health Assessment of Trace Elements in Fresh and Dry Fish From Lake Kariba, Siavonga, Zambia.

Poopedi Phaphedi M PM, Khulu Sinegugu S, Banda Kawawa K, Richards Heidi H et al.

This study investigated the levels of trace elements in two fish species, Kariba bream (Oreochromis mortimeri) and Kapenta (Limnothrissa miodon) from Lake Kariba in two consecutive years, 2021 and 2022. Both Kariba Bream fresh/sun-dried muscle and sun-dried Kapenta tissues were digested using a microwave digestion system and analyzed using Inductively Coupled Plasma Mass Spectrometry. Mean concentration of trace elements between the first and second sampling differed significantly (P > 0.05). In the first sampling, concentrations of trace elements in sun-dried bream occurred in the order Fe > Al > Cr > Zn > Mn > As while Se, Cu, Cd, Pb and Hg were not detected. Sun-dried Kapenta displayed Al > Fe > Zn > Mn > Cr > Cu > As > Se with Cd, Pb and Hg not detected. Fresh bream showed Fe > Al > Zn > Cr > Mn > Cu > Se, with Pb, As, Cd and Hg not detected. In the second sampling, the order was, Fe > Al > Zn > Cr > Mn > Se > Cu > As in sun-dried bream; Fe > Zn > Mn > Al > Cr > Cu > Se > As in sun-dried Kapenta with Cd, Pb and Hg not detected in both. Fresh bream showed; Fe > Al > Zn > Mn > Cr > Se > Cu > As > Pb with Cd and Hg not detected. Notably, the concentrations of Fe, Mn and Cr in some samples exceeded the recommended limits by FAO/WHO. The THQ and HI for some elements were above the threshold value of 1, indicating potential risk of non-carcinogenic to human health for long-term consumption. These findings highlight the need for further investigation into post-fish handling, including land-use activities in and around the lake.

PMID 42552490
阅读全文 →
PubMedCureus2026-08-05

Postprandial Glycemic Responses to Rice Porridge Versus Cooked Rice in Healthy Young Adults: A Randomized Controlled Crossover Study.

Kodama Kosuke K, Kayashita Atsuko A, Tsuji Niina N, Kakehashi Haruko H et al.

For individuals with dysphagia, rice porridge (RP) is a standard staple. However, its effect on postprandial glycemia compared to cooked rice (CR) - even with matched carbohydrate content - remains unclear. This study aimed to evaluate the impact of food form (CR vs. RP) on interstitial fluid glucose (IFG) levels using flash glucose monitoring (FGM). A randomized crossover study was conducted with 31 healthy university students (mean age 20.3 years). Subjects consumed either CR or RP, both standardized to 40.7 g of carbohydrates. IFG was measured using the FreeStyle Libre flash glucose monitoring system (Abbott Diabetes Care, Alameda, CA, USA) every 15 minutes for 120 minutes post-ingestion. Mastication was limited to 10 strokes per mouthful to simulate impaired oral processing. Primary outcomes were the incremental area under the curve (iAUC0-120) and time-specific IFG levels. Compared to CR, RP showed significantly higher IFG levels at 30, 45, and 60 minutes post-ingestion (p < 0.01). The iAUC was significantly greater for RP across all time intervals (0-30, 0-60, 0-90, and 0-120 min) (p < 0.05). No significant difference was observed in subjective fullness (Visual Analogue Scale (VAS)) at 120 minutes (p = 0.1). In healthy young adults, RP induces a more rapid and higher postprandial glucose response than CR despite identical carbohydrate content. This suggests that the increased surface area and gelatinization in porridge facilitate starch hydrolysis. Clinical nutritional management for patients requiring texture-modified diets should account for these glycemic differences.

PMID 42553572
阅读全文 →
PubMedClinics in orthopedic surgery2026-08-05

Digital Therapeutics for Postoperative Rehabilitation after Arthroscopic Rotator Cuff Repair: A Single-Center, Assessor-Blinded, Randomized Pilot Study.

Chang So-Youn SY, Kim Jong-Ho JH, Lee Youn Kyu YK, Shin Hyun Tae HT et al.

Home-based rehabilitation after arthroscopic rotator cuff repair (ARCR) often lacks objective monitoring. To address this limitation, we developed the ANAPA digital rehabilitation (DR) system, which includes a patient-facing mobile application for clinical efficacy evaluation (ANAPA ME) and a physician-facing measurement application for technical assessment (ANAPA PS). This study compared the safety and preliminary efficacy of ANAPA ME with conventional YouTube-based rehabilitation (CR), with an additional validation of the automated measurement functions in ANAPA PS. This single-center, assessor-blinded, randomized pilot study included 18 patients who had undergone ARCR. The participants were allocated to the DR group (n = 9) or CR group (n = 9) and followed identical postoperative rotator cuff exercise protocols. The program was conducted for 24 weeks postoperatively. The shoulder range of motion (ROM), muscle strength, and clinical outcomes (visual analog scale pain score, Constant shoulder score, Shoulder Pain and Disability Index, and EuroQol-5 Dimension-5 Level questionnaire) were evaluated at baseline and at follow-up up to 24 weeks postoperatively. Ultrasonography was performed at 24 weeks to evaluate the integrity of the repaired tendons. Automated ROM and muscle strength measurements of ANAPA PS were validated against digital goniometry and hand-held dynamometry at the 6-month follow-up, and measurement consistency was assessed using intraclass correlation coefficients (ICCs) and coefficients of variation (CV). Both the DR and CR groups demonstrated significant within-group improvements in ROM and clinical scores (p < 0.05). The DR group showed significantly greater improvements in specific ROM parameters, including forward flexion at 24 weeks and abduction, abduction-external rotation, and internal rotation at 18 and 24 weeks, compared with the CR group (p < 0.05). At 18 weeks, the internal rotation muscle strength was also significantly higher in the DR group than in the CR group (p < 0.05). A significant time-by-group interaction was observed for abduction, side-external rotation, and internal rotation (p < 0.05), suggesting a more consistent improvement pattern over time in the DR group compared with the CR group. In supplementary validation, ANAPA PS measurements showed high agreement with reference instruments (mean absolute error of 3.14° for ROM and 0.15-0.22 kgf for muscle strength). In consistency analysis, ANAPA PS showed higher repeatability and lower variability than digital goniometry (ICC = 0.99 vs. 0.97; CV = 1.61% vs. 11.7%, p < 0.001) and hand-held dynamometry (ICC = 0.97 vs. 0.39; CV = 2.1% vs. 13.8%, p < 0.001). In this exploratory pilot study, the ANAPA DR system demonstrated favorable trends compared with CR in patients after ARCR, suggesting the feasibility and safety of artificial intelligence-based digital therapeutics in postoperative shoulder rehabilitation. The supplementary validation further demonstrated the technical reliability and measurement consistency of the ANAPA PS automated measurement functions for monitoring rehabilitation outcomes.

PMID 42553900
阅读全文 →
PubMedHemaSphere2026-08-05

First-line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma.

Vitolo Umberto U, Falchi Lorenzo L, Andersson Per-Ola PO, Nijland Marcel M et al.

First-line (1L) bendamustine plus rituximab (BR) leads to high response rates in follicular lymphoma (FL), but maintaining durable remissions remains challenging. We report the 3-year follow-up from arm 3 of the phase 1b/2 EPCORE NHL-2 trial (NCT04663347) of epcoritamab, a subcutaneously administered CD3×CD20 bispecific antibody, combined with BR in patients with newly diagnosed FL. Twenty-five patients received epcoritamab plus BR, followed by epcoritamab monotherapy for up to 2 years. At a median follow-up of 41.3 months, the best overall response and CR rates were both 96%. The median time to CR was 1.5 (range 1-6) months. At 3 years, 87% of responders maintained CR. High CR rates were observed across subgroups, including 100% of patients with bulky disease (≥7 cm), 93% with Follicular Lymphoma International Prognostic Index score ≥3, and 100% with bone marrow involvement. The three-year progression-free survival and overall survival rates were 83% and 96%, respectively. Three patients progressed within 24 months of initiating treatment. Long-term data were consistent with prior reports and the known safety profiles of the individual agents, with no high-grade cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome events. Infections occurred in 92% of patients; COVID-19 was the most common (84%). Overall, 1L FL treatment with epcoritamab plus BR resulted in deep, durable responses beyond 3 years with a consistent safety profile. These results compare favorably with BR alone, although they require confirmation in further studies, and highlight the versatility of epcoritamab in combination with various standards of care and in improving outcomes in FL.

PMID 42553584
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多fluvoxamine